PMID- 34716775
OWN - NLM
STAT- MEDLINE
DCOM- 20230615
LR  - 20230615
IS  - 1435-1250 (Electronic)
IS  - 0340-1855 (Linking)
VI  - 82
IP  - 5
DP  - 2023 Jun
TI  - Relative efficacy and safety of Janus kinase inhibitors for the treatment of 
      active psoriatic arthritis: a network meta-analysis.
PG  - 408-416
LID - 10.1007/s00393-021-01119-8 [doi]
AB  - OBJECTIVE: To determine the relative effectiveness and safety of Janus kinase 
      (JAK) inhibitors in active psoriatic arthritis (PsA) patients. MATERIALS AND 
      METHODS: A Bayesian network meta-analysis was performed using data from 
      randomized controlled trials (RCTs) to evaluate the effectiveness and safety of 
      upadacitinib 30 mg, upadacitinib 15 mg, tofacitinib 10 mg, tofacitinib 5 mg, and 
      filgotinib 200 mg in active PsA patients. RESULTS: Five RCTs including 
      2539 patients fulfilled the inclusion criteria. The surface under the cumulative 
      ranking curve (SUCRA) revealed that filgotinib 200 mg had the highest probability 
      of reaching a 20% American College of Rheumatology (ACR20) response rate, 
      followed by upadacitinib 30 mg, upadacitinib 15 mg, tofacitinib 10 mg, 
      tofacitinib 5 mg, and placebo. Upadacitinib 30 mg had the highest probability of 
      achieving the ACR50 and ACR70 response rates, followed by upadacitinib 15 mg, 
      filgotinib 200 mg, tofacitinib 10 mg, tofacitinib 5 mg, and placebo. The SUCRA 
      rating based on the Psoriasis Area and Severity Index response rate of at least 
      75% (PASI75) showed that tofacitinib 10 mg had the highest probability of 
      achieving this response, followed by upadacitinib 15 mg, filgotinib 200 mg, 
      tofacitinib 5 mg, and placebo. Safety analyses evaluated adverse events (AEs) and 
      serious adverse events (SAEs), but no statistically relevant differences were 
      found. CONCLUSION: Based on the ACR response rates, filgotinib 200 mg and 
      upadacitinib 30 mg were the most effective, whereas tofacitinib 10 mg was the 
      most effective treatment for PsA based on PASI75. However, treatment options were 
      similar with regard to AEs and SAEs.
CI  - (c) 2021. Springer Medizin Verlag GmbH, ein Teil von Springer Nature.
FAU - Lee, Young Ho
AU  - Lee YH
AD  - Division of Rheumatology, Department of Internal Medicine, Korea University 
      College of Medicine, 73, Goryeodae-ro, Seongbuk-gu, 02841, Seoul, Korea (Republic 
      of). lyhcgh@korea.ac.kr.
FAU - Song, Gwan Gyu
AU  - Song GG
AD  - Division of Rheumatology, Department of Internal Medicine, Korea University 
      College of Medicine, 73, Goryeodae-ro, Seongbuk-gu, 02841, Seoul, Korea (Republic 
      of).
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
TT  - Relative Wirksamkeit und Sicherheit von Januskinase-Inhibitoren bei der 
      Behandlung der aktiven Psoriasis-Arthritis: eine Netzwerk-Metaanalyse.
DEP - 20211030
PL  - Germany
TA  - Z Rheumatol
JT  - Zeitschrift fur Rheumatologie
JID - 0414162
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Janus Kinase Inhibitors)
SB  - IM
MH  - Humans
MH  - *Antirheumatic Agents/therapeutic use
MH  - *Arthritis, Psoriatic/diagnosis/drug therapy
MH  - *Janus Kinase Inhibitors/adverse effects
MH  - *Arthritis, Rheumatoid/drug therapy
MH  - Network Meta-Analysis
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Efficacy
OT  - JAK inhibitors
OT  - Network meta-analysis
OT  - Psoriatic arthritis
OT  - Safety
EDAT- 2021/10/31 06:00
MHDA- 2023/06/15 06:42
CRDT- 2021/10/30 12:06
PHST- 2021/09/30 00:00 [accepted]
PHST- 2023/06/15 06:42 [medline]
PHST- 2021/10/31 06:00 [pubmed]
PHST- 2021/10/30 12:06 [entrez]
AID - 10.1007/s00393-021-01119-8 [pii]
AID - 10.1007/s00393-021-01119-8 [doi]
PST - ppublish
SO  - Z Rheumatol. 2023 Jun;82(5):408-416. doi: 10.1007/s00393-021-01119-8. Epub 2021 
      Oct 30.